- Home
- CNDT vs IGMS Comparison
CNDT vs IGMS Comparison
Compare CNDT & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNDT
- IGMS
- Stock Information
- Founded
- CNDT 2016
- IGMS 1993
- Country
- CNDT United States
- IGMS United States
- Employees
- CNDT N/A
- IGMS N/A
- Industry
- CNDT Business Services
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- CNDT Consumer Discretionary
- IGMS Health Care
- Exchange
- CNDT Nasdaq
- IGMS Nasdaq
- Market Cap
- CNDT 594.4M
- IGMS 528.6M
- IPO Year
- CNDT N/A
- IGMS 2019
- Fundamental
- Price
- CNDT $4.39
- IGMS $7.37
- Analyst Decision
- CNDT Buy
- IGMS Buy
- Analyst Count
- CNDT 1
- IGMS 8
- Target Price
- CNDT $9.00
- IGMS $16.25
- AVG Volume (30 Days)
- CNDT 1.1M
- IGMS 213.0K
- Earning Date
- CNDT 02-12-2025
- IGMS 11-08-2024
- Dividend Yield
- CNDT N/A
- IGMS N/A
- EPS Growth
- CNDT N/A
- IGMS N/A
- EPS
- CNDT 2.20
- IGMS N/A
- Revenue
- CNDT $3,509,000,000.00
- IGMS $2,918,000.00
- Revenue This Year
- CNDT N/A
- IGMS $386.95
- Revenue Next Year
- CNDT N/A
- IGMS N/A
- P/E Ratio
- CNDT $1.94
- IGMS N/A
- Revenue Growth
- CNDT N/A
- IGMS 57.64
- 52 Week Low
- CNDT $2.96
- IGMS $6.17
- 52 Week High
- CNDT $4.44
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- CNDT 61.32
- IGMS 31.53
- Support Level
- CNDT $4.15
- IGMS $7.00
- Resistance Level
- CNDT $4.44
- IGMS $10.80
- Average True Range (ATR)
- CNDT 0.18
- IGMS 0.96
- MACD
- CNDT 0.03
- IGMS -0.10
- Stochastic Oscillator
- CNDT 86.36
- IGMS 8.33
About CNDT Conduent Incorporated
Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments namely Commercial Industries which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas of which the majority of revenue is generated in the United States.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.